当归芍药散改善认知功能的研究进展

当归芍药散（danggui shaoyao san，DSS）是收录在汉代张仲景《金匮要略》中的著名方剂，原为治疗“妇人怀妊，腹中㽲痛”、“妇人腹中诸疾痛”而设，为中医健脾祛湿、养血调肝的著名方剂。临床多用于妇科疾病的治疗。近年发现当归芍药散具有神经保护作用，尤其对认知功能具有一定改善作用，其作用机制主要与调控雌激素水平、抑制氧化应激以及神经元突触等转导通路及相关信号分子有关。当归芍药散作为潜在的阿尔茨海默病及其他中枢神经退行性疾病治疗药物将日益受到关注，该文对当归芍药散化学成分和药理作用的研究进展进行综述。     

评价消风散合黄连解毒汤治疗湿疹效果及价值

目的:探讨评价消风散合黄连解毒汤治疗湿疹效果及价值。方法:选择2017年5—12月治疗湿疹的患者54例作为对象,随机数字表分为对照组(27例)和观察组(27例)。对照组给予常规盐酸西替利嗪片治疗的方法,观察组采用消风散合黄连解毒汤治疗,15 d后对两组治疗方法的患者血清白细胞介素(Interleukin,IL)-4、γ-干扰素(γ-Interferon,IFN-γ)水平和临床治疗效果进行评估,比较两组湿疹患者体内的血清IL-4、IFN-γ含量以及患者治愈、显效、好转、无效以及总有效率的情况。结果:治疗前后两组患者IL-4、IFN-γ差异无统计学意义(P>0.05)。经15 d治疗后,观察组血清IL-4、IFN-γ水平相较于对照组有明显改善,差异有统计学意义(P<0.05),观察组患者总有效率高于对照组,临床治疗效果显著优于对照组(P<0.05)。结论:将消风散合黄连解毒汤治疗用于湿疹,相较于盐酸西替利嗪片治疗,患者血清水平更佳,临床疗效更好,值得推广应用。     

生脉散合六味地黄汤加减治疗糖尿病的效果观察

目的:探讨对糖尿病患者给予生脉散合六味地黄汤加减治疗后获得的临床效果。方法:选择我院2015年5月-2017年4月收治的84例糖尿病患者作为实验对象;数字奇偶法分组。比照组(42例)予以西药治疗;实验组(42例)给予生脉散合六味地黄汤加减治疗;对比用药效果。结果:实验组糖尿病患者治疗总有效率、血糖水平、用药后不同时间段并发症发生率以及各项血脂指标水平均优于比照组明显(P<0.05)。结论:糖尿病患者于临床接受生脉散合六味地黄汤加减治疗后,利于病情疗效提升、血糖控制水平提升以及不同时间段并发症发生率降低。     

以“芪英三两三”组方经验为指导治愈顽固慢性再生障碍性贫血1例

慢性再生障碍性贫血属于临床血液系统常见疾病之一，发病率呈逐年升高趋势，病程长，易反复，对患者的生活质量形成严重影响。姜苗教授认为慢性再生障碍性贫血不仅与肾虚相关，且与脾胃升降功能联系密切，强调从脾论治，抓住“虚”“瘀”“毒”3个病理因素，活用“芪英三两三”组方加减，健脾益肾，化瘀解毒。文章以完全治愈1则顽固慢性再障合并继发血小板减少病案为例，探讨姜教授治疗慢性再生障碍性贫血思路及用药方案。     

Pump Speed Optimization in Patients Implanted With the HeartMate 3 Device

Background

Pump speed optimization in patients implanted with a ventricular assist device represents a major challenge during the follow-up period. We present our findings on whether combined invasive hemodynamic ramp tests and cardiopulmonary exercise testing (CPX) can help optimize patient management.

Efficacy of a Fibrin Sealant (Tissucol Duo) for the Preventionof Lymphocele after Laparoscopic Pelvic Lymphadenectomy:A Randomized Controlled Trial

Study ObjectiveTo assess the efficacy of Tissucol Duo (Baxter AG, Vienna, Austria) fibrin sealant in decreasing the incidence of lymphocele (LC) after pelvic laparoscopic lymph node dissection using harmonic shears.DesignRandomized controlled trial (Canadian Task Force classification level I).SettingTertiary referral and educational center.PatientsSeventy-four patients randomized to the use of sealant per hemipelvis.InterventionFibrin sealant.Measurements and Main ResultsAfter bilateral pelvic lymphadenectomy a fibrin sealant was used in 1 hemipelvis but not the other, applied in 41 patients (55.4%) to the left and 33 patients (44.6%) to the right hemipelvis. The primary outcome was the incidence of LC after surgery in symptomatic and asymptomatic patients. Imaging (ultrasound, computed tomography, and magnetic resonance) was performed to detect LC at 3, 6, and 12 months after surgery. Overall, 26 patients (35.1%) developed LC, and 4 were symptomatic (5.4%). Allowing patients to serve as their own treatment group and control, the hemipelvis treated with Tissucol Duo corresponding to the treatment group and that not treated to the control group, LCs were found in 17 (23%) and 14 (19%) cases, respectively, but the difference was not significant. The mean initial LC maximum diameter was 27.1 mm (standard deviaiotn, 35.2), and LCs tended to decrease in size during the first year to a mean of 8.7 mm.ConclusionApplication of Tissucol Duo fibrin sealant after laparoscopic pelvic lymphadenectomy using ultrasonic shears does not decrease the occurrence of symptomatic or asymptomatic LC.